Rubius is advancing its new class of cellular medicines called Red Cell Therapeutics (RCTs) — red blood cells engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent, and allogeneic cellular therapies . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge